Purinoreceptors and VZV Vasculopathy (P1.263)
Conclusions:Overall, VZV infection caused a transient rise in extracellular ATP. Importantly, we found that aside from its known antiplatelet effects, P2Y12 antagonist clopidogrel also inhibits VZV infection, independent of downstream inhibition of glycoprotein IIB/IIIA, and may serve as an alternative antiviral therapy for VZV vasculopathy.Disclosure: Dr. Wyborny has nothing to disclose. Dr. Choe has nothing to disclose. Dr. Totaro has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva as a speaker. Dr. Gerasimovskaya has nothing to disclose. Dr. Gilden has nothing to disclose. Dr. Nagel has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Wyborny, A., Choe, A., Traktinskiy, I., Gerasimovskaya, E., Gilden, D., Nagel, M. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research
More News: Antiviral Therapy | Brain | Clopidogrel | Genetics | Hepatitis | Merck | Neurology | Pharmaceuticals | Plavix | Stroke